Ana P. Lacerda

Statistics

Publications

Citations

1.6K

H-Index

Active since

2008

Affiliations

AbbVie (United States)(Current)

University of California San Diego

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Icahn School of Medicine at Mount Sinai

University of Calgary

Ana P. Lacerda is an author at AbbVie (United States) specializing in inflammatory bowel disease, crohn disease pharmacotherapy, and inflammatory bowel disease therapy.

ORCID

Publications per year

2008–2024

Publications

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

Edward V. Loftus, Julián Panés, Ana P. Lacerda et al. · New England Journal of Medicine · 2023 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

William J. Sandborn, Brian G. Feagan, Edward V. Loftus et al. · Gastroenterology · 2020 · 317 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Gerd R Burmester, Stanley Cohen, Kevin Winthrop et al. · RMD Open · 2023 · 210 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

Gerd R Burmester, Robert Landewé, Mark C. Genovese et al. · Annals of the Rheumatic Diseases · 2016 · 109 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

William J. Sandborn, Brian G. Feagan, Julián Panés et al. · Gastroenterology · 2017 · 85 citations

Medicine, Pharmacology, Pharmacotherapy +9

1–5 of 21